by Acute ischemic stroke (AIS) occurs due to interrupted blood flow to the brain which can lead to long term brain damage or death if not treated on time. AIS treatment aims to restore blood flow to the brain and reduce damage caused by interrupted blood supply. Thrombolytic therapy involving drugs that dissolve blood clots such as tissue plasminogen activator (tPA) is the standard treatment administered within 3-4.5 hours of onset of symptoms. Endovascular therapies which use catheters to mechanically remove or dissolve clots have improved treatment outcomes when administered within 6 hours of onset. The growing elderly population which is more prone to strokes, rising prevalence of risk factors such as obesity, diabetes and physical inactivity are fueling the need for effective AIS treatment options.
The global Acute Ischemic Stroke (AIS) Market is estimated to be valued at US$ 12 Billion in 2023 and is expected to exhibit a CAGR of 18% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends: One of the key trends in the AIS market is the emergence of improved endovascular therapies. Newer devices aimed at improving recanalization rates and outcomes are being introduced. For instance, the use of stent retrievers rather than first generation Merci Retrievers have significantly improved functional independence and mortality outcomes. Ongoing research is also evaluating the use of thrombectomy in combination with thrombolysis to optimize treatment effects. Development of minimally invasive thrombectomy devices is another area gaining attention to enable treatment in smaller hospitals. These advancements are expected to drive faster adoption of endovascular therapies and push the market growth over the forecast period.
Porter’s Analysis
Threat of new entrants: The threat of new entrants is low as this is an established market which requires significant investment and expertise to enter.
Bargaining power of buyers: The bargaining power of buyers is moderate as there are many treatment options available for patients with acute ischemic stroke.
Bargaining power of suppliers: The bargaining power of suppliers is moderate as there are many pharmaceutical and medical device companies supplying treatment products and solutions.
Threat of new substitutes: The threat of new substitutes is low as there are limited treatment options available for acute ischemic stroke currently.
Competitive rivalry: Competition is high among existing key players to develop new and innovative treatment solutions.
Key Takeaways
The global acute ischemic stroke (AIS) market size is expected to witness high growth over the forecast period of 2023 to 2030. The global Acute Ischemic Stroke (AIS) Market is estimated to be valued at US$ 12 Billion in 2023 and is expected to exhibit a CAGR of 18% over the forecast period 2023 to 2030.
North America is currently dominating the market due to high awareness levels and advanced healthcare infrastructure in countries like the US and Canada. Europe is also experiencing significant growth due to rising government initiatives to create awareness about stroke in the region. Asia Pacific is poised to be the fastest growing region owing to the presence of lucrative opportunities in countries like China, India and Japan. Rising geriatric population, growing incidence of lifestyle diseases, increasing healthcare expenditure are some of the key factors driving the growth of the AIS market in Asia Pacific.
Key players operating in the acute ischemic stroke market are Abbott Laboratories, Boston Scientific Corporation, Bayer AG, Medtronic Plc, Johnson & Johnson Services, Inc. Stryker Corporation. These players are focusing on new product launches and strategic collaborations with other companies to strengthen their market position.
